Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 39,215 shares of the firm’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $211.61, for a total transaction of $8,298,286.15. Following the completion of the transaction, the president directly owned 1,311,095 shares in the company, valued at $277,440,812.95. This trade represents a 2.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stephen Hoge also recently made the following trade(s):
- On Monday, November 16th, Stephen Hoge sold 39,160 shares of Moderna stock. The shares were sold at an average price of $219.66, for a total transaction of $8,601,885.60.
- On Thursday, October 15th, Stephen Hoge sold 39,145 shares of Moderna stock. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40.
- On Wednesday, October 14th, Stephen Hoge sold 39,224 shares of Moderna stock. The stock was sold at an average price of $213.48, for a total transaction of $8,373,539.52.
- On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22.
- On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The shares were sold at an average price of $146.07, for a total value of $5,883,845.67.
Moderna Stock Down 2.6%
Shares of MRNA opened at $194.18 on Friday. The stock has a 50 day moving average price of $207.87 and a two-hundred day moving average price of $100.37. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47.
Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. During the same period in the previous year, the firm earned ($0.51) EPS. The business’s revenue for the quarter was up 29.2% compared to the same quarter last year. On average, analysts forecast that Moderna, Inc. will post -5.40 earnings per share for the current year.
Institutional Trading of Moderna
A number of hedge funds have recently made changes to their positions in MRNA. BlackRock Inc. bought a new position in shares of Moderna during the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP bought a new stake in shares of Moderna in the 2nd quarter worth approximately $564,272,000. Aberdeen Group plc raised its holdings in shares of Moderna by 6,931.1% during the third quarter. Aberdeen Group plc now owns 1,054,306 shares of the company’s stock valued at $203,028,000 after acquiring an additional 1,039,311 shares in the last quarter. Wellington Management Group LLP lifted its stake in Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after acquiring an additional 103,977 shares during the period. Finally, Merck & Co. Inc. purchased a new stake in Moderna in the second quarter worth $161,642,545. 75.33% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
MRNA has been the topic of a number of research reports. Citigroup reaffirmed a “sell” rating on shares of Moderna in a report on Friday, October 23rd. TD Cowen reiterated a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Berenberg Bank upped their price objective on shares of Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a report on Friday, September 11th. The Goldman Sachs Group increased their target price on shares of Moderna from $137.00 to $195.00 and gave the stock a “neutral” rating in a research report on Monday, November 9th. Finally, Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $120.25.
View Our Latest Report on Moderna
More Moderna News
Investors following MRNA have been watching these news items:
- Positive Sentiment: A report says Morgan Stanley sees potential for substantial share-price appreciation, offering a more optimistic view amid recent volatility. Article: Morgan Stanley Forecasts Strong Price Appreciation
- Negative Sentiment: Investors are concerned that Moderna’s 2027 cash costs could reach $4 billion. The spending burden, alongside uncertain revenue from its expanding vaccine and oncology pipeline, raises questions about funding its next phase of growth. Article: Moderna's 2027 Cash Costs
- Neutral Sentiment: Bireme Capital disclosed that it sold its Moderna position after the stock’s rally. That reflects one manager’s portfolio decision, rather than a company announcement. Article: Bireme Capital Sold Moderna
Moderna Company Profile
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Read More
- Five stocks we like better than Moderna
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
